118 related articles for article (PubMed ID: 36194340)
1. The utilization and safety of apixaban for therapeutic anticoagulation in heart transplant population requiring routine endomyocardial biopsies.
Lindauer KE; Ingemi AI; McMahon MR; Lichvar A; Baran DA; Cameron C; Badiye A; Sawey EJ; Old W; Yao A; Yehya A; Herre JM
Clin Transplant; 2022 Dec; 36(12):e14828. PubMed ID: 36194340
[TBL] [Abstract][Full Text] [Related]
2. A retrospective analysis of anticoagulant safety among heart transplant recipients undergoing endomyocardial biopsy.
Stock JC; Carlquist J; Melnyk M; Smith S; Bole I; Patel V; Emani S; Foreman B; Hasan A; Franco V; Lampert BC; Haas GJ; Vallakati A; Ma J; Peng J; Boudoulas KD; Kahwash R
Clin Transplant; 2024 Feb; 38(2):e15254. PubMed ID: 38369817
[TBL] [Abstract][Full Text] [Related]
3. Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients.
Salerno DM; Thornberg ME; Lange NW; Hedvat J; Robbins H; Brown RS; Jennings DL; Scheffert J
Clin Transplant; 2021 Dec; 35(12):e14396. PubMed ID: 34165845
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
Kalani C; Awudi E; Alexander T; Udeani G; Surani S
Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single-center cohort study.
Bixby AL; Shaikh SA; Naik AS; Cotiguala L; McMurry K; Samaniego-Picota MD; Marshall VD; Park JM
Transpl Int; 2020 Jul; 33(7):740-751. PubMed ID: 32107804
[TBL] [Abstract][Full Text] [Related]
7. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
[TBL] [Abstract][Full Text] [Related]
8. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
9. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.
Lamberts M; Staerk L; Olesen JB; Fosbøl EL; Hansen ML; Harboe L; Lefevre C; Evans D; Gislason GH
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28196815
[TBL] [Abstract][Full Text] [Related]
10. Use of apixaban in children awaiting heart transplantation.
Benvenuto V; Hartje-Dunn C; Vo L; Hellinger A; Esteso P; Fynn-Thompson F; VanderPluym C
Pediatr Transplant; 2024 Feb; 28(1):e14632. PubMed ID: 37897124
[TBL] [Abstract][Full Text] [Related]
11. Risk of stroke and other thromboembolic complications after interruption of DOAC therapy compared with warfarin therapy in patients with atrial fibrillation: a retrospective cohort analysis.
Hellerman Itzhaki M; Greenberg N; Margalit I; Shochat T; Krause I; Goldberg E
J Investig Med; 2021 Dec; 69(8):1404-1410. PubMed ID: 34353884
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
13. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
15. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis.
Kuno T; Takagi H; Ando T; Sugiyama T; Miyashita S; Valentin N; Shimada YJ; Kodaira M; Numasawa Y; Briasoulis A; Burger A; Bangalore S
J Am Coll Cardiol; 2020 Jan; 75(3):273-285. PubMed ID: 31976865
[TBL] [Abstract][Full Text] [Related]
16. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
[TBL] [Abstract][Full Text] [Related]
17. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
Lester PA; Coleman DM; Diaz JA; Jackson TO; Hawley AE; Mathues AR; Grant BT; Knabb RM; Ramacciotti E; Frost CE; Song Y; Wakefield TW; Myers DD
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):942-948. PubMed ID: 28232327
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
[TBL] [Abstract][Full Text] [Related]
19. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
